Dapagliflozin reduces risk for hospitalization in patients with CKD with or without diabetes

A network of molecules and atoms of glass and crystals constitute a single system. 3D illustration

Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced the risk for hospitalization for any cause in patients with chronic kidney disease (CKD) with and without type 2 diabetes. The findings suggest that dapagliflozin should be considered in such patients. The study is published in Annals of Internal Medicine.

Parkinson’s medication improved blood pressure in teens with Type 1 diabetes

Previous article

Is course delivery model (entirely online vs mix of online and in-person classes) associated with college students’ mental health?

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations